BONE BIOLOGICS CORP (BBLG)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.57+1.86%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BBLG
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue advancing the first-in-human pilot clinical study of NB1 and complete patient enrollment by year-end 2026.
Stated as a priority in 2 of last 2 quarters. Management expects to complete patient enrollment in the NB1 pilot clinical study by year-end 2026. No revenue or operating income data is available to measure clinical progress, so delivery is based on management's stated timeline and remains on track.
“The Company continues to advance its first-in-human pilot clinical study of NB1, expecting to complete enrollment by year-end.”
“We expect to achieve value-creating events including completing enrollment in our pilot study by year-end.”
Maintain capital discipline supported by recent financing to extend operating runway through the second quarter of 2027.
Stated as a priority in 2 of last 2 quarters. The Company completed a private placement in July 2026 generating approximately $3.0 million upfront with potential additional $6.0 million from warrants, extending the operating runway through Q2 2027. Operating losses remain negative with operating income around -$808K in 2026-Q2, indicating ongoing capital discipline is critical. The trajectory is delivering as planned with runway extended.
“This financing extends our operating runway through Q2 2027, providing capital to execute priorities without near-term financing.”
“We expect to achieve value-creating events under our cost-efficient business model.”
Extend the validated shelf life of rhNELL-1 protein to support manufacturing flexibility and supply chain planning.
Stated as a priority in 2 of last 2 quarters. The validated shelf life of rhNELL-1 protein was extended from 24 months in 2025-Q4 to 29 months in 2026-Q2, supporting manufacturing and supply chain readiness. No revenue data is available to measure product impact, but the extension indicates progress in product stability.
“Validated shelf life of rhNELL-1 extended to 29 months, supporting manufacturing flexibility.”
“Extended shelf life milestone to 24 months achieved in December 2025.”
Add additional hospital sites in Australia and complete enrollment in the NB1 pilot study by year-end 2026.
Newly stated in 2025-Q4. Management planned to add hospital sites in Australia and complete pilot study enrollment by year-end 2025. No subsequent updates or financial data confirm progress, so delivery status is unclear.
“Adding additional hospital sites in Australia and completing enrollment in our pilot study by year-end.”
Control operating losses and cash flow burn to sustain operations amid ongoing clinical development.
Stated as a priority in 2 of last 2 quarters. Operating income was negative $733K in 2025-Q4 and worsened slightly to negative $808K in 2026-Q2, indicating ongoing operating losses and cash burn. Management emphasizes cost efficiency but financials show persistent losses, so progress is limited.
“Operating losses remain significant with operating income at -$808K in 2026-Q2.”
“Operating income was -$733K in 2025-Q4, reflecting ongoing losses.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Over the trailing year it converted 1.20x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
12 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.